The Effect of use of Pyridostigmine and Requirement of Vecuronium in Patients with Myasthenia Gravis
M Tripathi, S Kaushik, P Dubey
Department of Anaesthesiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Department of Anaesthesiology SGPGIMS, Lucknow - 226014
CONTEXT: Patients with myasthenia gravis receive pyridostigmine, an anticholinesterase agent, as a part of therapy. These patients demonstrate a heightened sensitivity towards non-depolarising muscle relaxants. Continuing pyridostigmine till the day of the surgery or omitting it on the night before surgery could provide variable results with regards to the effect of vecuronium. AIMS: Myographic evaluation of a dose of vecuronium in patients with myasthenia gravis on pyridostigmine therapy. SETTING AND DESIGN: A randomised, double-blind, clinical study conducted in a teaching hospital. SUBJECTS AND METHODS: Medically (oral pyridostigmine) well-controlled adult patients with myasthenia gravis who were posted for thymectomy, were randomly divided into two groups. Patients in Group 1 received their last dose of pyridostigmine on the night before surgery while those in Group 2 received even the morning dose of the drug on the day of surgery. Neostigmine (1-2 mg) intravenously was used as rescue medication. Vecuronium (0.01mg/kg) was used for intubation and muscle relaxation during trans-sternal thymectomy and its effect was reversed using neostigmine and atropine. RESULTS: Fourteen patients (7 in each group) belonging to both sexes were enrolled in the study. The intubating dose of vecuronium showed quicker onset time (155 sec or 2.7min approx.) and peak effect (99% T1 suppression) in patients belonging to Group 1, and 3/7 (43%) complained of respiratory discomfort while waiting for surgery. By giving the morning dose of pyridostigmine (Group 2), an identical intubating dose of vecuronium showed relative resistance (peak effect-97% T1 suppression) and delayed onset time (198 sec approx.). However, the reversal was complete at the end of surgery in both the regimens. CONCLUSIONS: Omission of the pyridostigmine dose on the day of surgery predisposed patients with myasthenia gravis to the possibility of respiratory discomfort and sensitivity to vecuronium. Continued administration significantly prolonged the onset time of vecuronium and the patients required a higher dose of vecuronium.
|How to cite this article:|
Tripathi M, Kaushik S, Dubey P. The Effect of use of Pyridostigmine and Requirement of Vecuronium in Patients with Myasthenia Gravis
.J Postgrad Med 2003;49:311-315
|How to cite this URL:|
Tripathi M, Kaushik S, Dubey P. The Effect of use of Pyridostigmine and Requirement of Vecuronium in Patients with Myasthenia Gravis
. J Postgrad Med [serial online] 2003 [cited 2022 May 24 ];49:311-315
Available from: https://www.jpgmonline.com/text.asp?2003/49/4/311/4972
Myasthenia gravis is an autoimmune disease, characterised by muscle weakness. It is related to the reduction in the functional acetylcholine (Ach) receptor population at the neuromuscular junction due to the presence of Ach-receptor antibodies. These patients have a variable response to muscle relaxants and are very sensitive towards non-depolarising muscle relaxants. It has been reported that vecuronium bromide in reduced doses is safe and effective and that larger the preoperative pyridostigmine dose, greater is the patient's sensitivity to the non-depolarizing agents. It has also been suggested that the sensitivity to vecuronium in patients with myasthenia gravis may be influenced by the anti-cholinesterase therapy., The continued use of anti-cholinesterase therapy prior to thymectomy in patients with myasthenia gravis has been a matter of ongoing debate. The aim of this prospective clinical study was to compare the effect of two different regimens of pyridostigmine in patients with myasthenia gravis undergoing thymectomy under balanced general anaesthesia.
Subjects and MethodsThe study was conducted in a hospital after obtaining clearance from the institution's Ethics committee. The sample size was estimated as 14 patients in both the groups taking into consideration that a difference of 30 seconds (with standard deviation of 20) would be clinically significant. Thus, 14 adult patients of both the sexes suffering from generalised myasthenia gravis, undergoing trans-sternal thymectomy between January 1995 and April 1999 were included in the study after obtaining informed consent. All patients were examined preoperatively and their respiratory and cardiac status evaluated. Patients were randomly divided into two study groups. In patients belonging to Group 1, pyridostigmine was stopped on the night before the surgery. In patients of Group 2, pyridostigmine was continued and the morning dose was administered with sips of water. Rescue neostigmine (1 to 2 mg) intravenously was allowed in case the patient complained of excessive muscle weakness or breathing difficulty. Oral lorazepam (2 mg) was administered to all patients on the night before surgery. In addition to the routine monitoring of ECG, estimation of non-invasive arterial blood pressure, temperature, and urine output, pulse oximetry and capnography, and neuromuscular monitoring were also done. The ulnar nerve was stimulated at the wrist using surface electrodes and the Myotest (Biometer ltd, Denmark). The adductor pollicis response on the thumb was recorded using Myograph-2000 (Biometer Ltd, Denmark). Mechanomyogrpahy was performed for the adductor pollicis response at 300 gm pre-tension. After the induction of anaesthesia with fentanyl (3 mcg/kg) and sodium thiopental (3-5mg/kg), the adductor response was stabilised at the titrated supra-maximal stimuli. Train-of-four (TOF) (4 stimuli at 2Hz) stimuli at 12-sec intervals were given at the ulnar nerve using surface electrodes by Myotest (Biometer Ltd, Denmark). Vecuronium (0.01mg/kg) was injected and its neuromuscular effect was monitored while assisting ventilation by facemask and maintaining anaesthesia by nitrous-oxide (65%) in oxygen with isoflurane (1%) on vaporiser setting with total fresh gas flow of 8l/min. Tracheal intubation was performed once T1 was suppressed up to 95% of control T1 height. Orotracheal intubation was graded clinically on a 1-4 scale: Grade 1-good jaw relaxation, vocal cords open, no response to intubation; Grade 2-good jaw relaxation, vocal cords open, minimal coughing on intubation; Grade 3-jaw relaxed, vocal cords moving, intubation requires firm pressure, marked coughing on endotracheal tube; Grade 4-intubation impossible due to poor jaw relaxation or closed vocal cords.
The effect of intubating dose of vecuronium was monitored to note the onset of intubation and the recovery time of intubation dose effect up to T1 amplitude 25% of its control. The incremental doses of vecuronium (one-fourth of the intubating dose) were repeated to maintain muscle relaxation at the level of with T1 just positive or maximum up to 10% of its control. Incremental dose intervals were also noted for each dose given during anaesthesia. At the end of surgery, the neuromuscular blockade was reversed with neostigmine (0.05mg/kg) and atropine (0.02mg/kg) prior to extubation. The extubation criteria were - adequate recovery of neuromuscular function as judged by a TOF ratio >0.95, a tidal volume of more than 5ml/kg during unassisted spontaneous breathing, a sustained head lift of more than 5 sec and a respiratory rate of less than 20/min. After surgery, all the patients were observed for 24 hrs in the high dependency unit with standby facility for assisted respiration, if necessary.
We recorded first dose response in terms of its peak effect (maximum block attained) and its onset time. Intubating dose effect (from the time of injection to recovery of T1 amplitude up to 25% of its control value) was also recorded. We also compared the duration of surgery, total dose of vecuronium used during total surgery (mg/kg), and success of extubation at the end of surgery. The occurrence of any side-effects peri-operatively and the need to use rescue neostigmine in both groups, were also recorded in the pre-designed proforma. The data were entered into the statistical package SPSS and the demographic data were compared using Student's' t' test. All proportions were compared using x2 test and the non-parametric method of statistical analysis, and the Mann Whitney U test was used to compare other parameters. Calculated p value of
The mean age of the studied patients was 33.7 years (range 20 to 40 years) and they weighed between 30 and 70 kg (mean 52.6 kg, SD 11.4 kg). The mean duration of illness was 15.1 months (range 6 to 27 months). None of the patients had any preoperative risk factors predicting the need for postoperative ventilator support. All patients were on pyridostigmine; 6 patients were also receiving prednisolone. The intubating dose in the form of one-tenth of the standard dose of vecuronium achieved 95% suppression of T1 in all patients giving excellent intubating conditions. The average (SD) duration of total anaesthesia time/surgery time was 180.3 min (55.5). Patient characteristics were similar in the two study groups [Table:1].
The median peak response of 97% T1 suppression in Group 2 patients was less than that in Group 1. The peak effect attained '0' twitch response in 6 patients in Group 1 and only in 2 patients in Group 2. The onset time (mean ± SD) for peak neuromuscular block effect of the intubations dose was significantly (P
Patients of myasthenia gravis are known to be extremely sensitive to the effects of non-depolarising muscle relaxants. The degree of sensitivity is variable even among patients who are in complete remission, although patients who have severe disease and require higher dose of pyridostigmine tend to be more sensitive than others. Hence, caution is required while using non-depolarising agents in patients with myasthenia gravis. The use of Atracurium infusion has been recommended during video-assisted thoracoscopic thymectomy. However, due to its exclusive cardiovascular stability vecuronium is still very commonly used in India. We used balanced anaesthesia with isoflurane (1%) in all our patients and one-tenth of the standard vecuronium dose was found to be safe and effective in producing optimum intubations and surgical conditions, with satisfactory reversal of the blockade postoperatively.
The total dose of vecuronium required in our study was almost half of that described by Baraka and Tabboush. Isoflurane has been reported to induce a significant depressant effect on neuromuscular transmission in myasthenic patients,, and it has also been reported to augment the effect of vecuronium., This is why we could get 95% twitch suppression with one-tenth of the vecuronium dose used for intubations in normal patients and could intubate all patients.
Pyridostigmine acts by inhibiting synaptic acetylcholinesterase, thus overcoming the deficit in receptor density in patients with myasthenia gravis. The high pyridostigmine concentration seemingly reduces the sensitivity of these patients to non-depolarisers. The variability in disease severity and in the response to non-depolarisers makes comparisons difficult. Eisenkraft et al compared the effects in 4 patients who were given pyridostigmine on the morning of surgery with those in whom it was withheld and failed to demonstrate any difference in sensitivity to vecuronium. Nilsson and Meretoja have reported that a higher daily dose of pyridostigmine was associated with increased sensitivity to vecuronium. Baraka and Tabboush compared vecuronium response in two patients. They reported a higher vecuronium response in myasthenic patients getting no anticholinergic therapy when compared to the effects noted in a patient who was on therapy. Paterson et al however, failed to demonstrate any differences in sensitivity to mivacurium in two patients receiving pyridostigmine as compared to two who were not.
In the present randomised, controlled, prospective study with a larger number of patients, we could reconfirm that the withdrawal of pyridostigmine prior to surgery clinically did not make a significant difference in terms of intubating condition at 95% twitch suppression. The omission of pyridostigmine on the night before surgery, however, did show greater sensitivity towards vecuronium during isoflurane anaesthesia and these patients required a lesser dose of vecuronium throughout surgery than the patients in whom pyridostigmine was continued. The patients were more prone to develop respiratory distress and even required rescue neostigmine. Contrary to a single case report of hypersensitivity to neostigmine and vecuronium in a sero-negative patient by Kim and Mangold, we could safely use neostigmine reversal at the end of surgery and successfully extubated all the patients.
Our study suggested that the optimisation of the medical condition with pyridostigmine until the morning of surgery followed by anaesthesia using isoflurane with one-tenth the standard intubating dose of vecuronium in patients with myasthenia gravis is safe. The omission of pyridostigmine on the night before surgery makes patients more susceptible to develop muscle weakness while waiting for the surgery and the patients show significant sensitivity towards vecuronium although neostigmine reversal is safe in all patients with myasthenia gravis.
|1||Nilsson E, Meretoja OA. Vecuronium dose-response and maintenance requirements in patients with myasthenia gravis. Anesthesiology 1990;73:28-32.|
|2||Baraka A, Tabboush Z. Neuromuscular response to succinylcholine-vecuronium sequence in three myasthenic patients undergoing thymectomy. Anesth Analg 1991;72:827-30.|
|3||Baraka A, Taha S, Yazbeck V, Rizkallah P. Vecuronium block in the myasthenic patient. Influence of anticholinesterase therapy. Anaesthesia 1993;48:588-90.|
|4||Leventhal SR, Orkin FK, Hirsh RA. Prediction of the need for post-operative mechanical ventilation in myasthenia gravis. Anesthesiology 1980;53:26-30.|
|5||Kim JM, Mangold J. Sensitivity to both vecuronium and neostigmine in a sero-negative myasthenic patient. Br J Anaesth 1989;63:497-500.|
|6||Tripathi M, Srivastava K, Misra SK, Puri GD. Peri-operative management of patients for video assisted thoracoscopic thymectomy in myasthenia gravis. J Post Graduate Med 2001;47:258-61.|
|7||Nilsson E, Muller K. Neuromuscular effects of isoflurane in patients with myasthenia gravis. Acta Anaesthesiol Scand 1990;34:126-31.|
|8||Rowbottom SJ. Isoflurane for thymectomy in myasthenia gravis. Anaesth Intensive Care 1989;17:444-7.|
|9||Kurahashi K, Maruta H. The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. Anesth Analg 1996;82:942-7.|
|10||Harrop-Griffiths W, Fauvel N, Plumley M, Feldman S. Pepecuronium versus high dose vecuronium. I. A comparison speed of onset and cumulation during isoflurane anaesthesia. Anaesthesia 1992;47:105-6.|
|11||Paterson IG, Hood JR, Russell SH, Weston MD, Hirsh NP. Mivacurium in the myasthenic patient. Br J Anaesth 1994;73:494-8.|
|12||Eisenkraft JB, Book WJ, Papatestas AE. Sensitivity to vecuronium in myasthenia gravis: a dose-response study. Can J Anaesth 1990;37:301-6.|